Effects of Pegylated interferon α-2b combined with Tenofovir Amibufenamide in treatment of patients with chronic hepatitis B
Objective:To observe effects of Pegylated interferon α-2b combined with Tenofovir Amibufenamide in treatment of patients with chronic hepatitis B.Methods:A prospective study was conducted on 92 patients with chronic hepatitis B admitted to the hospital from December 2021 to September 2022.According to the random number table method,they were divided into control group(n=46)and study group(n=46).The control group was treated with Tenofovir Amibufenamide,while the study group was treated with Pegylated interferon α-2b on the basis of that of the control group.The total effective rate of treatment,the negative rates of hepatitis B virus(HBV)-DNA and hepatitis B virus e antigen(HBeAg),the levels of liver fibrosis indexes[monoamine oxidase(MAO),hyaluronic acid(HA),laminin(LN),type IV collagen(IV-C)]and the liver function indexes[total bile acid(TBA),alanine aminotransferase(ALT),total bilirubin(TBIL)],the liver elasticity value,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the study group was 91.30%(42/46),which was higher than 65.22%(30/46)in the control group,and the difference was statistically significant(P<0.05).The negative rates of HBV-DNA and HBeAg in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of HA,LN,MAO and IV-C in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of ALT,TBIL,TBA and liver elasticity in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Pegylated interferon α-2b combined with Tenofovir Amibufenamide in the treatment of the patients with chronic hepatitis B can improve the total effective rate of treatment,the HBV-DNA negative rate and the HBeAg negative rate,reduce the levels of liver fibrosis indexes,liver function indexes and liver elasticity value.Moreover,it is superior to single Tenofovir Amibufenamide treatment.
NETL
NSTL
万方数据
维普
